Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 18/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.58 |
| ▸ | MC4R | P32245 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4731110 | 0.86 | SLC6A2 (0.58) | SLC6A2SLC6A3SLC6A4MC4R | |
| SCHEMBL4732656 | 0.86 | SLC6A2 (0.58) | SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL4949114 | 0.83 | SLC6A2 (0.53) | SLC6A2SLC6A3SLC6A4MC4RKDM4E | |
| SCHEMBL4730527 | 0.83 | SLC6A2 (0.61) | SLC6A2SLC6A4MC4R | |
| Hydrochloric Acid SCHEMBL27655995 | 0.81 | SLC6A2 (0.48) | SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL4955940 | 0.76 | USP2 (0.41) | SLC6A2SLC6A3SLC6A4KDM4ESMN1; SMN2 | |
| SCHEMBL3976064 | 0.74 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3049907 | 0.74 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4976031 | 0.74 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4975031 | 0.74 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3328835-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | Arena Pharmaceuticals, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017023679-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2015066344-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| EP-2200997-A1 | SYNTHESIS OF DEUTERATED CATECHOLS AND BENZOÝD¨Ý1,3¨DIOXOLES AND DERIVATIVES THEREOF | Concert Pharmaceuticals Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2010028130-A2 | ANTIDEPRESSANT COMPOUNDS | CONCERT PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009035652-A1 | SYNTHESIS OF DEUTERATED CATECHOLS AND BENZO[D][1,3] DIOXOLES AND DERIVATIVES THEREOF | CONCERT PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| EP-1910322-A2 | NOVEL BENZO [D][1,3]-DIOXOL DERIVATIVES | Concert Pharmaceuticals Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007016431-A2 | NOVEL BENZO [D] [1,3]-DIOXOL DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2007-02-08 | — | — | WO | disclosed |